Although Tregs are reported to be increased in tumor-bearing patients or animals, and thereby suppress antitumor immunity (2–4), the evidence is in fact mixed (5): the increase of FOXP3+ T cells is associated with poor prognosis in hepatocellular cancer (6), whereas it is related to good prognosis in colorectal cancer (7). The gene discussed is FOXP3; the disease is neoplasm.